

Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome

Masaru Yamaguchi

Hirosaki Daigaku

Marino Suzuki

Hirosaki Daigaku

Moeri Funaba

Hirosaki Daigaku

Akane Chiba

Hirosaki Daigaku

Ikuo Kashiwakura (✉ ikashi@hirosaki-u.ac.jp)

Hirosaki Daigaku <https://orcid.org/0000-0002-7399-1445>

Research

Keywords: Acute radiation syndrome, Approved pharmaceutical drugs, Granulocyte colony-stimulating factor, Romiplostim, Radiation medical countermeasure

Posted Date: July 16th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-34653/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on August 3rd, 2020. See the published version at <https://doi.org/10.1186/s13287-020-01861-x>.

Abstract

Background: It has been reported that the high-dosage administration of domestically approved pharmaceutical drugs, especially granulocyte colony-stimulating factor (G-CSF) and romiplostim (RP), is a rapid and appropriate medical treatment for preventing severe acute radiation syndrome (ARS) of victims exposed to lethal total-body irradiation (TBI). However, it remains unclear whether or not the clinical dosage administration of these drugs can ameliorate TBI-induced ARS and related high mortality in order to find various drug treatment options and less toxic optimum protocol depending on the situation surrounding the radiological accidents.

Methods: We assessed the clinical dosage administration in combination with G-CSF and RP as intraperitoneal injection in C57BL/6J mice exposed to more than 7-Gy lethal dose of X-ray TBI for the survival study evaluated by the log-rank test. Bone marrow and splenic cells were collected on the 21st day, when 1 week have passed from last administration, to detect the level of cell apoptosis, intracellular reactive oxygen species (ROS), and nuclear factor erythroid 2-related factor 2 (Nrf2)-related anti-oxidative gene expressions, and enzyme-linked immune sorbent assay using sera was performed for cell senescence and inflammation status analyzed with one-way ANOVA and Tukey-Kramer or Bonferroni/Dunn multiple comparison tests.

Results: The combined once-daily administration of 10 µg/kg G-CSF for 4 times and 10 µg/kg RP once a week for 3 times improve the 30-day survival rate of lethal TBI mice compared with untreated TBI mice, accompanied by a gradual increase in the body weight and hematopoietic cell numbers. The radio-mitigative effect is probably attributed to the scavenging of ROS and the reduction in cell apoptosis. These changes were associated with the upregulation of Nrf2 and its downstream anti-oxidative targets in TBI mice. Furthermore, this combination modulated TBI-induced cell senescence and inflammation markers.

Conclusions: This study suggested that the clinical dosage administration in combination with G-CSF and RP may also have radio-mitigative effects on mice exposed to lethal TBI and may be a potent therapeutic agent for mitigating radiation-induced severe ARS.

Background

Total-body irradiation (TBI) exposure of greater than 1 Gy in the event of an unexpected radiological/nuclear accident results in well-understood acute adverse effects on the hematopoietic system due to this system's strong radio-sensitivity. This dysfunction derived from acute radiation syndrome (ARS) is characterized by dose-dependent bone marrow destruction, and at worst, individual death within a few months [1]. Therefore, appropriate medical treatments should be performed immediately after TBI in order to achieve reconstitution and restoration of hematopoiesis and avoid ARS-induced mortality. Following an accidental or deliberate radiological scenario accompanied by a large number of victims, the intake of appropriate medications using stably supplied and regularly stockpiled

approved pharmaceutical drugs is the most suitable initial treatment, as one should expect substantial delays in delivering good medical care to the affected population. While efforts to identify and develop radiation medical countermeasures (MCMs) for ARS were first initiated decades ago [2, 3], there are only three U.S. Food and Drug Administration-approved MCMs available that increase the survival in patients: two granulocyte colony-stimulating factors (G-CSFs) and the granulocyte macrophage colony-stimulating factor (GM-CSF) [4]. In Japan, there are four recombinant G-CSFs that have been approved [5]. However, while G-CSFs can address post-radiation neutropenia, they do not address the thrombocytopenia or excessive bleeding that occurs in ARS. MCMs that can address thrombocytopenia would likely have a positive effect on ARS patients when administered alone or in combination with a G-CSF, since the duration of severe thrombocytopenia appears to correlate with death to a greater extent than that of severe neutropenia and appears to be more clinically relevant to the survival in ARS [6]. The approval of cytokine use varies by country, and GM-CSFs, interleukin-3, and thrombopoietin (TPO), which are recommended as the principal therapeutic cytokines corresponding to ARS severity by the International Atomic Energy Agency [7], are not approved in Japan. We recently found that treatment with a combination of domestically approved drugs, such as a G-CSF (Neutrogen®) and the TPO receptor (TPOR) agonist romiplostim (RP; Romiplate®), rescues mice from lethal TBI [8–10]. Although the effectiveness of these drugs as a medical treatment for emergency radiation exposure has been reported, the necessary dosages reported were much higher than the clinically used dosages. It would therefore be desirable to identify suitable drug treatment options with a less-toxic therapeutic protocol. In addition, effective MCMs with low toxicity for emergency radiation medical care are needed while considering the medical situation or regulations of therapeutic goods in each country. In the present study, to establish an optimum therapeutic protocol using domestically approved pharmaceutical drugs to increase the survival of TBI exposed victims, we assessed various combinations of clinical dosage administrations of G-CSF and RP in mice exposed to a lethal TBI. These findings could be expected to contribute to emergency radiation medical care or reduction of side effects on normal tissues in radiotherapy.

Methods

Animal experiments

Seven-week-old female C57BL/6JJcl mice were delivered from the breeding facilities of Clea Japan (Tokyo, Japan). All mice were housed in a conventional clean room under a 12-h light/dark cycle. The mice had ad libitum access to sterilized standard laboratory mouse chow diet and drinking water. In the present study, the selection criteria applied prior to sacrifice were >20% loss of body weight and respiratory distress. All experiments were conducted according to the legal regulations in Japan and the Guidelines for Animal Experiments after obtaining approval from the animal experimental committee (approved number: G17001).

Lethal X-ray Tbi In Mice

After a week of acclimatization, eight-week-old mice were randomly subjected to varying lethal TBI doses of 7-, 7.25-, or 7.5-Gy of X-rays (150 kVp, 20 mA, 0.5-mm aluminum and 0.3-mm copper filters) at a dose rate of 1.0 Gy/min using an MBR-1520R X-ray generator (Hitachi Medical, Tokyo, Japan). Within 2 h after TBI, the mice were administered the medications described below. In addition to mice treated with TBI only, mice that received TBI and medication (TBI + medication), those treated with medication only, and those that did not receive either TBI or medication (control mice) were also evaluated in this study. The numbers of mice included in these experimental groups are indicated in the figure legends.

Drug Administration

The post-radiation treatment was performed within 2 h after TBI, and the TBI and non-TBI mice were administered different types of medications (Table 1). The four types of medications were delivered in combinations of the following two commercially available drugs based on our previous reports [8–10]: recombinant human G-CSF Neutrogin® (Chugai Pharmaceutical, Tokyo, Japan) and human TPOR agonist RP (Romiplate®; Kyowa Hakko Kirin, Tokyo, Japan). G-CSF or RP was intraperitoneally administered once-daily for 3 or 4 times or once a week for up to 4 times, respectively. The dose of G-CSF and RP was 10 µg/kg of body weight/day, which was the same as the clinically used dose [11–13]. Mice treated with TBI only and control mice alternatively received injections of normal saline solution as the vehicle (Otsuka Pharmaceutical, Tokyo, Japan) used to prepare the drugs. Peripheral blood was harvested from the fundus of mice anesthetized using isoflurane (Powerful Isoful; Zoetis, London, UK). The separated serum samples were stored at – 80 °C until the analysis.

Table 1
The four combinations of medications subsequent to lethal TBI.

Medication	Drugs	Administration days after radiation exposure						Total frequency (times)
		< 2-h	1-d	2-d	7-d	14-d	21-d	
#1	G-CSF	→	→	→				3
	RP	→			→			2
#2	G-CSF	→	→	→				3
	RP	→			→	→		3
#3	G-CSF	→	→	→				3
	RP	→			→	→	→	4
#4	G-CSF	→	→	→	→			4
	RP	→			→	→		3

Collection Of Bone Marrow And Splenic Cells

Bone marrow cells (BMCs) were harvested from both femurs by flushing with ethylenediaminetetraacetic acid-phosphate buffered saline (PBS), pH 7.4, containing 0.5% bovine serum albumin. To collect splenic cells, the spleen was removed and pressed with a spoon into Hanks' balanced salt solution. After centrifuging, the BMCs and splenic cells were treated with Gey's salt solution for red blood cell lysis. After removal of the lysed red blood cells, the viable BMCs and splenic cells were filtered through a 45- μ m strainer and counted using a hemocytometer (BurkerTurk; Sunlead Glass, Saitama, Japan) with the trypan blue dye exclusion method (Sigma-Aldrich®, St. Louis, MO, USA).

Cell Death Analyses

Apoptosis was analyzed using the fluorescein isothiocyanate (FITC) Annexin V apoptosis Detection Kit with propidium iodide (PI) (BioLegend, San Diego, CA, USA) according to the manufacturer's instructions. In brief, BMCs and splenic cells were harvested, washed and suspended in Annexin V binding buffer. The Annexin V-FITC and PI solution were then added to the cell suspension, which was incubated for 15 min at room temperature in the dark. The cells were then analyzed by flow cytometry (FC500; Beckman Coulter®, Fullerton, CA, USA). In the Annexin V/PI quadrant gating, cells were classified as annexin V-negative PI-negative, annexin V-positive PI-negative, or annexin V-positive PI-positive, representing viable, early apoptotic, and late apoptotic/necrotic cells, respectively.

Measurement Of Intracellular Reactive Oxygen Species (ros) Generation

The fluorescent probe 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H₂DCFDA) (Thermo Fisher Scientific, Boston, MA, USA) was used for the assessment of intracellular ROS, such as hydroxyl radical, hydrogen peroxide, and peroxynitrite. BMCs and splenic cells were incubated for 20 min with 5 μ M CM-H₂DCFDA in PBS at 37 °C in a humidified atmosphere with 5% CO₂. Unincorporated CM-H₂DCFDA was removed by washing with PBS. Each sample was resuspended in PBS and analyzed by flow cytometry.

Enzyme-linked Immunosorbent Assay (elisa) Analyses

The concentrations of plasminogen activator inhibitor (PAI-1), tumor necrosis factor α (TNF- α), and cyclin-dependent kinase inhibitor 2A (CDKN2A/p16^{INK4a}), in the serum were measured with commercially available ELISA kits according to the manufacturers' protocols. All samples subjected to these assays were quickly thawed serum. Each sample was individually placed in a well pre-coated with an antibody against the target protein and then incubated to allow binding of the antibodies immobilized at the bottom of the well. Subsequently, biotinylated antibodies for each of the antibodies and horseradish peroxidase-conjugated streptavidin were added and reacted according to the manufacturers' protocols.

After the 3-, 3', 5-, 5'- tetramethylbenzidine substrate addition and following stop solution reaction, the concentrations of the target protein were measured at an absorbance of 450 nm using a standard curve obtained from standard solutions. The ELISA kits for murine PAI-1, TNF- α , and CDKN2A/p16^{INK4a} were PAI-1 (SERPINE1) Mouse ELISA Kit (Thermo Fisher Scientific), Mouse TNF-alpha ELISA Kit (Protein Tech Japan, Tokyo), and Mouse CDKN2A ELISA kit (LifeSpan BioSciences, Seattle, WA, USA), respectively.

Total Rna Extraction

RNA, including miRNA, was extracted from BMCs and splenic cells using miRNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. The quality and concentration of the yielded RNA were assessed using a NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). All RNA samples had 260/280-nm absorbance ratios of 1.8-2.0.

Quantitative Reverse Transcription Polymerase Chain Reaction (qrt-pcr) Analysis

First-strand complementary DNA from RNA was synthesized using the SuperScript™ IV VILO™ Master Mix with ezDNase (Thermo Fisher Scientific) according to the manufacturer's instructions. qRT-PCR was performed using the Power SYBR® Green Master Mix (Applied Biosystems, Carlsbad, CA, USA) and a StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific). ATPase subunit 6 mRNA (*ATP6*) was used as an internal control for all reactions because the fluctuation of *ATP6* was the lowest among 16 housekeeping genes and 16 mouse orthologs of human internal standard genes analyzed with the TaqMan® Array Mouse Endogenous Control 96-well Plate (Thermo Fisher Scientific) in the preliminary test. We performed qPCR with the following typical amplification parameters: 95 °C for 10 min, followed by 40 cycles of 95 °C for 15-s and 60 °C for 1 min. Relative differences in the gene expression were determined by the $\Delta\Delta CT$ method. The mRNA expression of control mice was defined as the baseline. The oligonucleotide primer sets used in this analysis of related nuclear factor-erythroid-2-related factor 2 (Nrf2) target genes, such as heme oxygenase 1 (*Ho-1*), ferritin heavy polypeptide 1 (*Fth1*), NAD(P)H dehydrogenase quinone 1 (*Nqo1*), glutamate-cysteine ligase catalytic subunit (*Gclc*), glutamate-cysteine ligase modifier subunit (*Gclm*), glutathione reductase (*Gsr*), and thioredoxin reductase 1 (*Txnrd1*), and the internal control *ATP6* were purchased from Eurofins Genomics Inc. (Tokyo, Japan) (Table 2).

Table 2
Sequences of PCR primers

Gene	Primer sequence (5' to 3')
<i>Ho-1</i>	F: AGGGTCAGGTGTCCAGAGAA R: CTTCCAGGGCCGTGTAGATA
<i>Fth1</i>	F: TGGAGTTGTATGCCTCCTACG R: TGGAGAAAGTATTTGGCAAAGTT
<i>Nqo1</i>	F: AGCGTTCGGTATTACGATCC R: AGTACAATCAGGGCTCTTCTCG
<i>Gclc</i>	F: AGATGATAGAACACGGGAGGAG R: TGATCCTAAAGCGATTGTTCTTC
<i>Gclm</i>	F: TGA CTCACAATGACCCGAAA R: TCAATGTCAGGGATGCTTTCT
<i>Gsr</i>	F: ACTATGACAACATCCCTACTGTGG R: CCCATACTTATGAACAGCTTCGT
<i>Txnrd1</i>	F: TCTGAAGAAAAAGCCGTAGAGAA R: TTCCAATGGCCAAAAGAAAC
<i>ATP6</i>	F: CCATAAATCTAAGTATAGCCATTCCAC R: AGCTTTTTAGTTTGTGTCGGAAG
Note. F = forward primer, R = reverse primer.	

Statistical Analyses

Data are represented as the mean \pm standard deviation (SD). The levels of significance were calculated using the Excel 2016 software program (Microsoft, Redmond, WA, USA) with the Statcel3 add-on (OMS, Saitama, Japan). Survival studies data were analyzed using the Kaplan-Meier method followed by the Mantel-Cox (log-rank) test for the assessment of significant differences. *P* values of < 0.01 or 0.05 were considered to indicate statistical significance by *t*-test for the comparison between two groups. In addition, the data were analyzed with one-way ANOVA and Tukey-Kramer or Bonferroni/Dunn multiple comparison tests statistically significant. The statistical method used in each experiment is indicated in the figure legends.

Results

Survival rate following the clinical dosage administration in combination with approved pharmaceutical drugs

To determine the effects of the clinical dosage administration in combination with approved pharmaceutical drugs on the survival of mice exposed to high-dose (7 Gy) TBI, 4 combinations of 2 drugs (G-CSF and RP) were administered to mice within 2 h after X-irradiation. The combinations and schedules are summarized in Table 1. The doses of G-CSF and RP used in the present study (10 µg/kg of body weight/day) were the same as the clinically used doses. The survival rates with each medication are shown in Fig. 1. Mice exposed to the 7-Gy dose of TBI alone showed a 60% 30-day survival rate. In contrast, although no statistically significant difference was observed between mice treated with TBI only and those that received TBI and each medication, all combinations improved the 30-day survival rate to 90% (Fig. 1A-C). Combination #4 (once-daily G-CSF for 4 times and RP once a week for 3 times) showed a 100% 30-day survival rate (Fig. 1D). In order to evaluate the relationship between the lethal effect of a more than 7-Gy dose of TBI and the radio-mitigative effect of combination #4, G-CSF and RP were administered as per the protocol after TBI, and the survival was monitored for up to 30 days. When exposed to lethal doses of TBI (7.25 Gy), the 30-day survival rate of saline-treated mice was 20% (Fig. 1E). The administration of combination #4 significantly improved the survival rate to 80% ($P = 0.039$). In addition, while a 7.5-Gy dose of TBI was fatal in all saline-treated mice within 14 days, post-exposure treatment with combination #4 resulted in a 60% survival rate at 30 days ($P = 0.008$, Fig. 1F). These results indicated that combination #4 was the most suitable medication for improving the 30-day survival rate and subsequent studies were performed at a radiation dose of 7.25 Gy.

Mitigation Of Lethal Tbi-induced Hematopoietic Damages By Pharmaceutical Drugs

To assess the radio-mitigative effects of approved pharmaceutical drugs against a lethal 7.25-Gy dose of TBI-induced hematopoietic injury, the bone marrow and spleen of TBI mice treated with or without combination #4 were examined. At day 21 post-TBI, when 1 week have passed from last administration, the survival rate of TBI mice that received vehicle was approximately 20%, whereas all TBI mice survived following the administration of combination #4 ($P = 0.0135$, Fig. 2A). While TBI mice treated with or without medications showed a similar growth until day 12, the body weights of the TBI mice that received medications were higher than those of the mice that received vehicle on day 21, although not to a significant degree ($P = 0.14$, Fig. 2B). At that time, the femurs and spleen were collected from the surviving mice. A significant decrease in the splenic size was observed in the TBI mice (Fig. 2C). However, in the mice treated with TBI and medications, splenic atrophy was not apparent and the splenic size on day 21 was 2-fold higher than that in the control mice. The splenic weight was also found to be markedly reduced in the TBI mice (data not shown), but this weight was drastically higher than that in the control mice following medication (Fig. 2D). Splenic endogenous colonies serve as an indicator of hematopoiesis, which is a crucial and indispensable factor dictating hematopoietic recovery post TBI

and, consequently, the survival [14, 15]. In addition, the number of viable splenic cells was significantly decreased after TBI and remained low until day 21 (Fig. 2E). The recovery of the decreased number of viable splenic cells occurred following medication administration. In contrast, however, while the number of viable BMCs in the TBI mice treated with medications gradually increased compared to the TBI-only group, the counts remained nearly six-fold lower than the counts in the control mice on day 21, suggesting incomplete recovery (Fig. 2F). These results suggest that hematopoietic stresses mobilize hematopoietic stem/progenitors from the bone marrow to the spleen and induce extramedullary hematopoiesis [16, 17], and the administration of combination #4 to mice exposed to lethal TBI may enhance/recover the hematopoietic function in the spleen.

Reduction In Apoptotic Cell Death By Pharmaceutical Drugs

Since TBI may induce irreparable DNA damage that can lead to disordered cell growth and cell apoptosis [18], a flow cytometric analysis of annexin V/PI quadrant gating of apoptotic cell death was performed to assess the effects of clinical dosage administration of approved pharmaceutical drugs on the BMC and splenic cell survival on day 21. In Fig. 3A and 3D, cells were classified as annexin V-negative PI-negative, annexin V-positive PI-negative, or annexin V-positive PI-positive, representing viable, early apoptotic, and late apoptotic/necrotic cells, respectively. The percentage of early apoptotic BMCs was significantly increased by TBI, but the medications markedly reduced this trend by two-fold compared to that in the TBI mice (Fig. 3B). However, the percentage of late apoptotic/necrotic BMCs also increased remarkably with TBI and tended to be suppressed by medications, although not to a significant degree (Fig. 3C). In contrast, there was a notable increase in the proportions of early apoptotic and late apoptotic/necrotic splenic cells in the TBI mice (46.1 ± 0.8 and 51.5 ± 0.8 , respectively). The medications significantly reduced apoptotic cell death in both populations (32.6 ± 6.0 and 5.0 ± 1.4 , respectively) ($P < 0.01$, Fig. 3E-F). Regarding the population of late apoptotic/necrotic splenic cells in particular, medications significantly suppressed the counts to nearly 90% of those observed in the TBI mice, leading to the attainment of baseline control levels. These findings show that the administration of combination #4 was able to prevent TBI-induced apoptosis of hematopoietic cells *in vivo* and contribute to the alleviation of hematopoietic failure.

Scavenging Of Tbi-induced Intracellular Ros By Pharmaceutical Drugs

TBI may induce apoptotic cell death, resulting in myelosuppression, partly via the induction of oxidative stress in hematopoietic systems [19]. We examined intracellular ROS generation in response to TBI. ROS generation in splenic cells and BMCs after cell collection at day 21 was analyzed by flow cytometry using CM-H₂DCFDA staining, which can be detected by reacting with intracellular ROS, such as hydroxyl radicals, hydrogen peroxide, and peroxynitrite. As shown in Fig. 4A and 4B, the sustained generation of intracellular ROS in splenic cells was significantly elevated at day 21 after TBI compared to control mice.

Treatment with combination #4 markedly attenuated the elevation of ROS production in the spleen, suggesting that this medication can effectively scavenge TBI-induced ROS production, especially hydroxyl radicals, hydrogen peroxide, and peroxynitrite, while in BMCs, the amount of ROS in the TBI mice was significantly decreased compared to other groups (Fig. 4C). According to the representative histogram of ROS production in BMCs, a small peak was found to the right of the large peak in the control mice and TBI mice treated with medication but was not observed in the TBI mice (Fig. 4D). More-differentiated and mature cells (corresponding to gate F) were presumably almost depleted in the TBI mice (Fig. 4E). These results indicate that the administration of combination #4 acts as an inhibitor (antioxidant) of TBI-mediated ROS generation.

Regulation of the Nrf2-mediated antioxidant defense system by pharmaceutical drugs

Nrf2, a central regulator of the endogenous antioxidant defense, has been implicated in the response to redox homeostasis [20]. To determine the underlying mechanisms by which the medication of combination #4 protected TBI mice against oxidative stress, we evaluated the expression of the Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 signaling pathway's downstream genes, such as *Ho-1*, *Fth1*, *Nqo1*, *Gclc*, *Gclm*, *Gsr*, and *Txnrd1*, involved in redox reactions in BMCs and splenic cells by qRT-PCR. *ATP6* was used as an internal control for all reactions because the fluctuation of *ATP6* was the lowest among 16 housekeeping genes and 16 mouse orthologs of human internal standard genes analyzed with the TaqMan® Array Mouse Endogenous Control 96-well Plate (data not shown). The mRNA expression of control mice was defined as the baseline and normalized to calculate the relative differences. The expression of *Nqo1* ($P < 0.05$) and *Gclm* ($P < 0.01$) was significantly increased on day 21 in BMCs of TBI mice treated with medication compared to control mice (Fig. 5A). However, the expression of *Gsr* decreased significantly. In contrast, a qRT-PCR analysis revealed that the administration of combination #4 resulted in a marked increase in the *Fth1* ($P < 0.01$), *Txnrd1* ($P < 0.05$), and especially *Nqo1* ($P < 0.01$) and *Gclm* ($P < 0.01$) expression in splenic cells at 21 days after TBI compared with the levels in control mice (Fig. 5B). These observations suggest that this medication reduces TBI-induced oxidative stress, possibly by regulating the Keap1/Nrf2 signaling pathway. Regarding Nrf2 target genes, such as *Ho-1* and *Gclc*, no significant differences were observed in BMCs and splenic cells in this study.

Evaluation of the inflammatory/senescence profiles induced by TBI

To investigate the effects of combination #4 on TBI-induced inflammation and cell senescence, the serum inflammation markers PAI-1 and TNF- α and aging marker CDKN2A/p16^{INK4a} were measured using commercially available ELISA kits. We evaluated the serum concentration of PAI-1, which is induced by radiation, resulting in endothelial cell impairment and potentially leading to multiple organ failure [21]. Interestingly, a dramatic increase in the concentration of serum PAI-1 was observed in the TBI mice on day 21; PAI-1 was reduced 7-fold in the TBI mice treated with medication and was comparable to that in the control mice (Fig. 6A). The serum concentration of TNF- α in non-TBI mice treated with medication was found to be significantly higher than that in the control mice and TBI mice treated with or without medication (Fig. 6B). CDKN2A/p16^{INK4a} has shown an increased expression in hematopoietic stem cells

of TBI mice and been used as a biomarker of cell senescence [22]. The serum CDKN2A/p16^{INK4a} levels were significantly increased by TBI, but significant suppression was observed with the medication (Fig. 6C). However, this concentration in the TBI mice treated with medication was still higher than that in control mice on day 21. These results suggest that the administration of combination #4 to lethally irradiated mice suppresses inflammation and cell senescence.

Discussion

TBI exposure from radiotherapy or a radiological/nuclear accident results in adverse effects on cell/tissue structures and functions [23, 24]. Hematopoietic tissues are the most sensitive to radiation, and the rapid depletion of peripheral blood cells is a hallmark of hematopoietic disorders in ARS, which can ultimately lead to individual death. Various MCMs for ARS, such as thiol-containing compounds, cytokines, growth factors, and inhibitors of apoptosis, have been designed and reported [25, 26], but some candidate drugs have a relatively high toxicity and are clinically inconsequential due to poor radio-protection [27]. We previously reported that treatment with the combination of domestically approved pharmaceutical drugs (e.g. G-CSF and RP) enhances the survival of mice exposed to lethal TBI [8–10]. Although the effectiveness of these drugs as a medical treatment for emergency radiation exposure has been known, the necessary dosages reported were much higher than the clinically used dosages, and it would be desirable to identify suitable drug treatment options with less-toxic therapeutic protocol, depending on the situation surrounding the radiological accidents. Based on the 30-day survival rate in this study, the clinical dosage administration of G-CSF once-daily for 4 times and RP once a week for 3 times (combination #4, Table 1) were shown to completely rescue mice from 7-Gy TBI (Fig. 1D). Furthermore, this medication drastically improved the 30-day survival rate of mice exposed to lethal 7.25- or 7.5-Gy TBI (80%, Fig. 1E or 60%, Fig. 1F, respectively) compared to the untreated TBI mice, suggesting that the clinical dosage administration in combination with G-CSF and RP may have radio-mitigative effects on lethal TBI mice and can be used as a potent therapeutic agent to mitigate radiation-induced severe ARS.

The administration of combination #4 was confirmed to increase the splenic weight (Fig. 2D) and the appearance of endogenous splenic colonies (Fig. 2C), and recovery in viable splenic cells was also observed (Fig. 2E). However, the number of viable BMCs in the TBI mice treated with medication was still lower than in the control mice, suggesting an incomplete recovery (Fig. 2F). The spleen in mice, unlike humans, is a major hematopoietic tissue, and the increase in the splenic weight is correlated with the hematopoietic function in the spleen [28]. Hematopoietic stresses are well known to mobilize hematopoietic stem cells from the bone marrow to the spleen, which induces extramedullary hematopoiesis [16]. Bykov et al. also reported that lignin-derived polyphenolic composition with ammonium molybdate improved the 30-day survival rate and increased the formation of endogenous splenic colony-forming units, indicating that the radio-mitigative effects are mediated by the enhancement of extramedullary hematopoiesis in the spleen [29]. It is therefore possible that the

administration of combination #4 also enhanced the hematopoietic function in the spleen instead of the damaged bone marrow of mice exposed to lethal TBI.

Low-linear energy transfer ionizing radiation generates ROS that can lead to biological damage and alter cellular signaling pathways involved in cell cycle arrest, DNA damage, and cell death apoptosis [30, 31]. On day 21 after TBI, the sustained generation of intracellular ROS in splenic cells was significantly elevated compared to control mice (Fig. 4A-B). The administration of combination #4 markedly attenuated the elevation of ROS production in the spleen. Regarding BMCs, the amount of ROS in the TBI mice treated with medication was equivalent to the levels in control mice (Fig. 4C-D). Furthermore, cell death apoptosis was significantly increased in both BMCs (Fig. 3A-C) and splenic cells (Fig. 3D-F) but suppressed by the administration of combination #4. Recently, Vlachodimitropoulou et al. reported that Eltrombopag, which is a small molecule oral TPOR agonist, is a powerful iron chelator that mobilizes iron and ferritin, reduces ROS [32], and TPO, which is an important and non-redundant cytokine for hematopoietic stem cell maintenance and expansion, also exert a protective effect on iron-overload induced apoptosis by inhibiting oxidative stress and suppressing the mitochondrial pathways in cardiomyocytes [33]. In addition, TPOR agonists have been reported to support DNA repair in hematopoietic stem/progenitor cell populations by modulating the efficiency of the DNA-dependent protein kinase catalytic subunit-dependent non-homologous end-joining pathway [34, 35]. On day 21 after TBI, the foci of γ -H2AX, is the first step in recruiting and localizing DNA repair proteins [36], in BMCs and splenic cells of TBI mice treated with administration of combination #4 were undetectable and comparable to the control mice (data not shown). Consistent with previous studies, it was suggested that the administration of combination #4 had various influences acting on the ROS scavenging, DNA repair promoting, and subsequently suppressing apoptosis in mice exposed to lethal TBI.

The mRNA expression of *Nqo1* and *Gclm* in BMCs (Fig. 5A) and *Fth1*, *Nqo1*, *Gclm* and *Txnrd1* (Fig. 5B) in splenic cells was up-regulated in TBI mice treated with combination #4 compared with control mice, which may be involved in the mitigative effects on the radiation damage in hematopoietic organs. Among the genes with an increased expression, *Nqo1* and *Gclm* in particular showed a marked increase in both BMCs and splenic cells at 21 days after TBI compared with the levels in control mice. *Nqo1* is an important enzyme in the human antioxidant defense system and is known to protect cell/tissues from various cytotoxic quinones and oxidative stress [37, 38]. *Gclm* forms a dimer with *Gclc* and becomes glutamate cysteine ligase, a rate-limiting enzyme that produces glutathione, which has an antioxidant effect [39]. Ma et al. reported that ferulic acid protects human umbilical vein endothelial cells from radiation-induced oxidative stress by increasing the mRNA of antioxidant-related genes, such as *GCLM* and *NQO1*, in radiated cells via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways [40]. In addition, epicatechin mitigates radiation-induced intestinal injury and promotes intestinal regeneration by suppressing oxidative stress through the promotion of Nrf2 translocation from the cytoplasm to nucleus, which activates the expression of *NQO1* [41]. Furthermore, theaflavin, a polyphenolic compound from black tea, has the potential to be used as a radio-protective agent to ameliorate TBI-induced hematopoietic injury [42]. These effects of theaflavin were associated with a decline in ROS levels and DNA damage in irradiated hematopoietic stem cells, and oxidative stress was

reduced mainly by up-regulating Nrf2 and its downstream targets *Nqo1*. Therefore, the administration of combination #4 to mice exposed to lethal TBI enhanced the intrinsic antioxidant systems, resulting in an increase in the splenic weight and viable cell counts, the appearance of endogenous colonies, and the suppression of apoptosis, which can help prevent mortality of mice exposed to lethal TBI. In contrast, the expression of *Gsr* in the BMCs of TBI mice treated with combination #4 was significantly decreased compared to that of control mice (Fig. 5A). The expression of Nrf2 target genes may be temporarily reduced because the half-life of Nrf2 is 20 min, or the Nrf2 target genes activated by the administration of combination #4 may be differ between the spleen and bone marrow.

The inflammatory marker PAI-1 (Fig. 6A) and the cell senescence marker CDKN2A/p16^{INK4a} (Fig. 6C) were markedly expressed, and the up-regulation of both was significantly suppressed by treatment. PAI-1 is an important regulator of cellular senescence, and its inhibition produces anti-oxidative enzymes and suppresses ROS production/ROS-induced aging marker p16^{INK4a} expression, leading to the suppression of cell senescence in endothelial cells [43, 44]. The serum PAI-1 and CDKN2A/p16^{INK4a} levels were drastically down-regulated in this study, suggesting that the administration of combination #4 might induce not only the reduction of TBI-induced vascular endothelial damage but also the suppression of cell/individual senescence.

This study revealed a significant improvement in the 30-day survival rate of mice exposed to lethal TBI following the clinical dosage administration in combination with the approved pharmaceutical drugs G-CSF and RP. These may function as effective radio-mitigative agents by activating the Keap1/Nrf2-dependent antioxidative response. TBI-induced severe oxidative stress ultimately induces cell death, which is involved in various disease states. The combination of pharmaceutical drugs used in this study may be able to be applied as an effective radio-mitigative agents to reduce severe oxidative stress induced by TBI and is expected to contribute to emergency radiation medical care and the reduction of side effects on normal tissues in radiotherapy. As long as the threat of nuclear disaster exists, such efforts in the field of radiation emergency medicine, including the development of effective drug therapies, will be necessary.

Conclusions

The clinical dosage administration in combination with the approved pharmaceutical drugs G-CSF and RP showed an effective radio-mitigative ability for mice exposed to lethal TBI and can therefore be used as a potent therapeutic agent to mitigate radiation-induced severe hematopoietic ARS.

Abbreviations

ARS; acute radiation syndrome, ATP6; ATPase subunit 6 mRNA, BMCs; bone marrow cells, CDKN2A/p16^{INK4a}; cyclin-dependent kinase inhibitor 2A, CM-H₂DCFDA; 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate, acetyl ester, FITC; fluorescein isothiocyanate, Fth1; ferritin heavy polypeptide 1, Gclc; glutamate-cysteine ligase catalytic subunit, Gclm; glutamate-cysteine ligase modifier

subunit, G-CSF; granulocyte colony-stimulating factor, GM-CSF; granulocyte macrophage colony-stimulating factor, Gsr; glutathione reductase, Ho-1; heme oxygenase 1, Keap1; Kelch-like ECH-associated protein 1, MCMs; medical countermeasures. Nqo1; NAD(P)H dehydrogenase quinone 1, Nrf2; nuclear factor erythroid 2-related factor 2, PAI-1; plasminogen activator inhibitor-1, PI; propidium iodide, qRT-PCR; quantitative reverse transcription polymerase chain reaction, ROS; reactive oxygen species, RP; romiplostim, SD; standard deviation, SPCs; splenic cells, TBI; total-body irradiation, TNF- α ; tumor necrosis factor α , TPO; Thrombopoietin, TPOR; TPO receptor, Txnrd1; thioredoxin reductase 1.

Declarations

Ethics approval and consent to participate

All experiments were conducted according to the legal regulations in Japan and the Guidelines for Animal Experiments after obtaining approval from the animal experimental committee (approved number: G17001).

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by a KAKENHI Grant-in-Aid for Scientific Research (A) (No. 16H02667 IK) and partially supported by a KAKENHI Grant-in-Aid for Young Scientists (No. 18K18190 MY).

Authors' contributions

I.K. and M.Y. designed the study; M.Y., M.S., M.F, A.C. and I.K. performed the experiments; M.Y. and I.K. were major contributor in writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Singh VK, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures. *Int J Radiat Biol.* 2017; 93: 851-869.
2. Singh VK, Garcia M, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status. *Int J Radiat Biol.* 2017; 93: 870-884.
3. Singh VK, Hanlon BK, Santiago PT, Seed TM. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part III. Countermeasures under early stages of development along with 'standard of care' medicinal and procedures not requiring regulatory approval for use. *Int J Radiat Biol.* 2017; 93: 885-906.
4. Cheema AK, Byrum SD, Sharma NK, Altadill T, Kumar VP, Biswas S, et al. Proteomic Changes in Mouse Spleen after Radiation-Induced Injury and its Modulation by Gamma-Tocotrienol. *Radiat Res.* 2018; 190: 449-463.
5. Johnke RM, Sattler JA, Allison RR. Radioprotective agents for radiation therapy: future trends. *Future Oncol.* 2014; 10: 2345-2357.
6. Li M, Gu MM, Lang Y, Shi J, Chen BPC, Guan H, et al. The vanillin derivative VND3207 protects intestine against radiation injury by modulating p53/NOXA signaling pathway and restoring the balance of gut microbiota. *Free Radic Biol Med.* 2019; 145: 223-236.
7. Satyamitra M, Cary L, Dunn D, Holmes-Hampton GP, Thomas LJ, Ghosh SP. CDX-301: a novel medical countermeasure for hematopoietic acute radiation syndrome in mice. *Sci Rep.* 2020; 10: 1757.
8. Singh VK, Newman VL, Seed TM. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review. *Cytokine.* 2015; 71: 22-37.
9. Stickney DR, Dowding C, Authier S, Garsd A, Onizuka-Handa N, Reading C, et al. 5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression. *Int Immunopharmacol.* 2007; 7: 500-505.
10. Kashiwakura I. Overview of Radiation-protective Agent Research and Prospects for the Future. *Jpn J Med Phys.* 2017; 52: 285-295.
11. Hirouchi T, Ito K, Nakano M, Monzen S, Yoshino H, Chiba M, et al. Mitigative Effects of a Combination of Multiple Pharmaceutical Drugs on the Survival of Mice Exposed to Lethal Ionizing Radiation. *Curr Pharm Biotechnol* 2015; 17: 190-199.

12. Yamaguchi M, Hirouchi T, Yokoyama K, Nishiyama A, Murakami S, Kashiwakura I. The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation. *Sci Rep.* 2018; 8: 10659.
13. Yamaguchi M, Hirouchi T, Yoshioka H, Watanabe J, Kashiwakura I. Diverse functions of the thrombopoietin receptor agonist romiplostim rescue individuals exposed to lethal radiation. *Free Radic Biol Med.* 2019; 136: 60-75.
14. Diana H, Nino M. Romiplostim (Nplate), a Treatment Option for Immune (Idiopathic) Thrombocytopenic Purpura. *P T.* 2009; 34: 482-485.
15. Keating GM. Lenograstim: a review of its use in chemotherapy-induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization. *Drugs.* 2011; 71: 679-707.
16. Park S, Yoon SS, Lee JH, Park JS, Jang JH, Lee JW. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia. *Int J Hematol.* 2016; 103: 44-52.
17. Park E, Ahn GN, Lee NH, Kim JM, Yun JS, Hyun JW, et al. Radioprotective properties of eckol against ionizing radiation in mice. *FEBS Lett.* 2008; 582: 925-930.
18. Zhou Y, Mi MT. Genistein stimulates hematopoiesis and increases survival in irradiated mice. *J Radiat Res.* 2005; 46: 425-433.
19. Inra CN, Zhou BO, Acar M, Murphy MM, Richardson J, Zhao Z, et al. A perisinusoidal niche for extramedullary haematopoiesis in the spleen. *Nature.* 2015; 527: 466-471.
20. Jothy SL, Saito T, Kanwar JR, Chen Y, Aziz A, Yin-Hui L, et al. Radioprotective activity of *Polyalthia longifolia* standardized extract against X-ray radiation injury in mice. *Phys Med.* 2016; 32: 150-161.
21. Zhang J, He Y, Shen X, Jiang D, Wang Q, Liu Q, et al. γ -H2AX responds to DNA damage induced by long-term exposure to combined low-dose-rate neutron and γ -ray radiation. *Mutat Res Genet Toxicol Environ Mutagen.* 2016; 795: 36-40.
22. Shao L, Feng W, Li H, Gardner D, Luo Y, Wang Y, et al. Total body irradiation causes long-term mouse BM injury via induction of HSC premature senescence in an *Ink4a*- and *Arf*-independent manner. *Blood.* 2014; 123: 3105-3115.
23. Ma Q. Role of *nrf2* in oxidative stress and toxicity. *Annu Rev Pharmacol Toxicol.* 2013; 53: 401-426.
24. Hazawa M, Yasuda T, Saotome-Nakamura A, Tomiyama K, Obara C, Goto T, et al. Intra- and extracellular plasminogen activator inhibitor-1 regulate effect of vitronectin against radiation-induced endothelial cell death. *Vascul Pharmacol.* 2016; 87: 150-158.
25. Sharpless NE. *Ink4a/Arf* links senescence and aging. *Exp Gerontol.* 2004; 39: 1751-1759.
26. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. *Int J Med Sci.* 2012; 9: 193-199.
27. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. *Nat Rev Cancer.* 2006; 6: 702-713.

28. Macková NO, Fedorocko P. Effect of liposomal muramyl tripeptide phosphatidylethanolamine and indomethacin on hematopoietic recovery in irradiated mice. *Physiol Res.* 2002; 51: 511-521.
29. Bykov VN, Drachev IS, Kraev SY, Maydin MA, Gubareva EA, Pigarev SE, et al. Radioprotective and radiomitigative effects of BP-C2, a novel lignin-derived polyphenolic composition with ammonium molybdate, in two mouse strains exposed to total body irradiation. *Int J Radiat Biol.* 2018; 94: 114-123.
30. Mikkelsen RB, Wardman P. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. *Oncogene.* 2003; 22: 5734-5754.
31. Quintiliani M. The oxygen effect in radiation inactivation of DNA and enzymes. *Int J Radiat Biol Relat Stud Phys Chem Med.* 1986; 50: 573-594.
32. Vlachodimitropoulou E, Chen YL, Garbowski M, Koonyosying P, Psaila B, Sola-Visner M, et al. Eltrombopag: a powerful chelator of cellular or extracellular iron (III) alone or combined with a second chelator. *Blood.* 2017; 130: 1923-1933.
33. Chan S, Chan GC, Ye J, Lian Q, Chen J, Yang M. Thrombopoietin Protects Cardiomyocytes from Iron-Overload Induced Oxidative Stress and Mitochondrial Injury. *Cell Physiol Biochem.* 2015; 36: 2063-2071.
34. de Laval B, Pawlikowska P, Petit-Cocault L, Bilhou-Nabera C, Aubin-Houzelstein G, Souyri M, et al. Thrombopoietin-increased DNA-PK-dependent DNA repair limits hematopoietic stem and progenitor cell mutagenesis in response to DNA damage. *Cell Stem Cell.* 2013; 12: 37-48.
35. de Laval B, Pawlikowska P, Barbieri D, Besnard-Guerin C, Cico A, Kumar R, et al. Thrombopoietin promotes NHEJ DNA repair in hematopoietic stem cells through specific activation of Erk and NF- κ B pathways and their target, IEX-1. *Blood.* 2014; 123: 509-519.
36. Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. *In Vivo.* 2008; 22: 305-309.
37. Lienhart WD, Strandback E, Gudipati V, Koch K, Binter A, Uhl MK, et al. Catalytic competence, structure and stability of the cancer-associated R139W variant of the human NAD(P)H: quinone oxidoreductase 1 (NQO1). *FEBS J.* 2017; 284: 1233-1245.
38. Oh ET, Kim JW, Kim JM, Kim SJ, Lee JS, Hong SS, et al. NQO1 inhibits proteasome-mediated degradation of HIF-1 α . *Nat Commun.* 2016; 7: 13593.
39. Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. *Free Radic Biol Med.* 1999; 27: 922-935.
40. Ma ZC, Hong Q, Wang YG, Tan HL, Xiao CR, Liang QD, et al. Ferulic acid protects human umbilical vein endothelial cells from radiation induced oxidative stress by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase pathways. *Biol Pharm Bull.* 2010; 33: 29-34.
41. Li Y, Ma S, Zhang Y, Yao M, Zhu X, Guan F. (-)-Epicatechin mitigates radiation-induced intestinal injury and promotes intestinal regeneration via suppressing oxidative stress. *Free Radic Res.* 2019; 53: 851-864.

42. Han X, Zhang J, Xue X, Zhao Y, Lu L, Cui M, et al. Theaflavin ameliorates ionizing radiation-induced hematopoietic injury via the NRF2 pathway. *Free Radic Biol Med.* 2017; 113: 59-70.
43. Nadia AM, Shereen MS. The effect of naringenin on the role of nuclear factor (erythroid-derived 2)-like2 (Nrf2) and haem oxygenase 1 (HO-1) in reducing the risk of oxidative stress-related radiotoxicity in the spleen of rats. *Environ Toxicol.* 2019; 34: 788-795.
44. Elzi DJ, Lai Y, Song M, Hakala K, Weintraub ST, Shiio Y. Plasminogen activator inhibitor 1–insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. *Proc Natl Acad Sci USA.* 2012; 109: 12052-12057.
45. Ghosh AK, Rai R, Park KE, Eren M, Miyata T, Wilsbacher LD, et al. A small molecule inhibitor of PAI-1 protects against doxorubicin-induced cellular senescence. *Oncotarget.* 2016; 7: 72443-72457.

Figures




Figure 1

Kaplan-Meier plots for the survival of mice treated with combinations of commercially available drugs. Mice were intraperitoneally administered a clinical dosage (10 µg/kg of body weight/day) of G-CSF and RP, starting within 2 h after 7-Gy dose of TBI. As shown in Table 1, the medications were administered in 4 different combinations (n = 10 in each group): [A] G-CSF once-daily for 3 times and RP once a week for 2 times, [B] G-CSF once-daily for 3 times and RP once a week for 3 times, [C] G-CSF once-daily for 3 times and RP once a week for 4 times, and [D] G-CSF once-daily for 4 times and RP once a week for 3 times. In addition, mice were intraperitoneally administered the clinical dosage of G-CSF once-daily for 4 times and RP once a week for 3 times starting within 2 h after [E] 7.25 Gy or [F] 7.5 Gy of TBI (n = 5 in each group). Mice treated with TBI only received injections of the normal saline solution as vehicle. "7 Gy + GRP", "7.25 Gy + GRP" or "7.5 Gy + GRP" and "7 Gy", "7.25 Gy" or "7.5 Gy" indicated the results of TBI mice with and without medications, respectively. Statistically significant differences were evaluated by the log-rank test compared with TBI only (P < 0.05).




Figure 2

Commercially available drugs attenuate lethal TBI-induced hematopoietic reduction. Mice were intraperitoneally administered the clinical dosage (10 $\mu\text{g}/\text{kg}$ of body weight/day) of G-CSF once-daily for 4 times and RP once a week for 3 times (GRP #4) starting within 2 h after exposure to a 7.25-Gy dose of TBI. Mice treated with TBI only received injections of the normal saline solution as vehicle. “7.25 Gy + GRP” and “7.25 Gy” indicate the results of TBI mice with and without GRP #4, respectively. [A] Mitigative

effects of GRP #4 administered immediately post-TBI are represented in a Kaplan-Meier survival curve until day 21 (n = 5 in each group). Statistically significant difference was evaluated by the log-rank test compared with TBI only (P < 0.05). [B] Body weight changes in the surviving mice (n = 5 in each group). [C] Representative photographs of splenic endogenous colonies on day 21 are shown. Scale bars, 1 cm. [D] Splenic weights and total viable cell numbers in the [E] spleen and [F] bone marrow observed in the TBI and control mice treated with or without GRP #4 (n = 5 per group). The data are expressed as the means \pm SD. Statistically significant differences were evaluated by one-way ANOVA and the multiple comparison tests (**P < 0.01, *P < 0.05).




Figure 3

The inhibition of TBI-induced apoptotic cell death by commercially available drugs. Mice were intraperitoneally administered the clinical dosage (10 μ g/kg of body weight/day) of G-CSF once-daily for 4 times and RP once a week for 3 times starting within 2 h after a 7.25-Gy dose of TBI. Mice treated with TBI only received injections of the normal saline solution as vehicle. “7.25 Gy + GRP” and “7.25 Gy” indicate the results of TBI mice with and without medications, respectively. [A] Representative flow cytometry plots of annexin V/PI stained populations in BMCs. [B] The number of annexin V-positive PI-negative populations in the bone marrow (n = 5 in each group). [C] The number of annexin V/PI double-positive populations in the bone marrow (n = 5 in each group). [D] Representative flow cytometry plots of annexin V/PI stained populations in splenic cells (SPCs). [E] The number of annexin V-positive PI-negative populations in the spleen (n = 5 in each group). [F] The number of annexin V/PI double-positive populations in the spleen (n = 5 in each group). The data are expressed as the means \pm SD. Statistically significant differences were evaluated by one-way ANOVA and the multiple comparison tests (**P < 0.01).




Figure 4

The alleviation of TBI-induced intracellular ROS generation by commercially available drugs. Mice were intraperitoneally administered the clinical dosage (10 $\mu\text{g}/\text{kg}$ of body weight/day) of G-CSF once-daily for 4 times and RP once a week for 3 times (GRP #4) starting within 2-h after a 7.25-Gy dose of TBI. Mice treated with TBI only received injections of the normal saline solution as vehicle. "7.25 Gy + GRP" and "7.25 Gy" indicate the results of TBI mice with and without GRP #4, respectively. [A] The levels of ROS in splenic cells (SPCs) detected by the CM-H2DCFDA mean fluorescence intensity (MFI) ($n = 5$ in each group) and [B] the representative histogram of ROS levels by flow cytometry. [C] The levels of ROS in

BMCs detected by the CM-H2DCFDA MFI (n = 5 in each group) and [D] the representative histogram of ROS levels by flow cytometry. [E] The representative flow cytometry plots of forward and side scatter of BMCs are shown. The data are expressed as the means \pm SD. Statistically significant differences were evaluated by one-way ANOVA and the multiple comparison tests (**P < 0.01, *P < 0.05).




Figure 5

The regulation of the expression of Nrf2 signaling pathway's downstream genes. Mice were intraperitoneally administered a clinical dosage (10 μ g/kg of body weight/day) of G-CSF once-daily for 4 times and RP once a week for 3 times (GRP #4) starting within 2 h after a 7.25-Gy dose of TBI. Mice treated with TBI only received injections of the normal saline solution as vehicle. "7.25 Gy" and "0 Gy" indicate the results of GRP #4 treated mice with and without TBI, respectively. The relative quantitative mRNA expression of [A] *Nqo1*, *Gclm*, and *Gsr* in BMCs, and [B] *Nqo1*, *Gclm*, *Fth1*, and *Txnrd1* in splenic cells, respectively, analyzed by qRT-PCR is presented as the means \pm SD of the fold change (bar graph) compared with control mice (dotted line) (n = 5 in each group). ATP6 was used as an internal control for

all reactions. Statistically significant differences were evaluated by one-way ANOVA and the multiple comparison tests (**P < 0.01 and *P < 0.05 against control, or ††P < 0.01 and †P < 0.05 against drug combination mice without TBI).




Figure 6

The effects of commercially available drugs on inflammation and cell senescence markers in serum. Mice were intraperitoneally administered a clinical dosage (10 μ g/kg of body weight/day) of G-CSF once-daily for 4 times and RP once a week for 3 times (GRP #4) starting within 2 h after a 7.25-Gy dose of TBI.

Mice treated with TBI only received injections of the normal saline solution as vehicle. "7.25 Gy + GRP" and "7.25 Gy" indicate the results of TBI mice with and without GRP #4, respectively. Peripheral blood was harvested from the orbital venous plexus of mice anesthetized using isoflurane and serum samples were separated. The serum inflammation markers [A] PAI-1 and [B] TNF- α and the aging marker [C] CDKN2A/p16INK4a were analyzed by an ELISA (n = 5 in each group). The data are expressed as the means \pm SD. Statistically significant differences were evaluated by one-way ANOVA and the multiple comparison tests (**P < 0.01).